Functional polymorphisms in LPS receptors CD14 and TLR4 are not associated with disease susceptibility or Campylobacter jejuni infection in Guillain-Barré patients

Journal of Neuroimmunology

Volumn 150, Issue 1-2, 2004, Pages 132-138

  Geleijns, Karin ^a   Jacobs, Bart C ^a   Van Rijs, Wouter ^a   Tio Gillen, Anne P ^a   Laman, Jon D ^a   Van Doorn, Pieter A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Campylobacter jejuni; CD14; Guillain Barr syndrome; LightCycler; Single nucleotide polymorphism (SNP); Toll like receptor 4

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CD14 ANTIGEN; TOLL LIKE RECEPTOR 4;

ADOLESCENT; ADULT; AGED; ARTICLE; CAMPYLOBACTER JEJUNI; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; GRAM NEGATIVE INFECTION; GUILLAIN BARRE SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYNEUROPATHY; PRIORITY JOURNAL; SEROLOGY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD14; AUTOANTIBODIES; CAMPYLOBACTER INFECTIONS; CAMPYLOBACTER JEJUNI; CHILD; DISABILITY EVALUATION; FEMALE; GANGLIOSIDES; GENETIC PREDISPOSITION TO DISEASE; GUILLAIN-BARRE SYNDROME; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECEPTORS, CELL SURFACE; SEROLOGIC TESTS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTORS;

EID: 1842636929     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2004.01.003     Document Type: Article

References (38)

1. Agnese D.M., Calvano J.E., Hahm S.J., Coyle S.M., Corbett S.A., Calvano S.E., Lowry S.F. Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J. Infect. Dis. 186:2002;1522-1525.
2. Allos B.M. Association between Campylobacter infection and Guillain-Barré syndrome. J. Infect. Dis. 176:1997;S125-S128.
3. Ang C.W., Endtz H.P., Jacobs B.C., Laman J.D., de Klerk M.A., van der Meché F.G., van Doorn P.A. Campylobacter jejuni lipopolysaccharides from Guillain-Barré syndrome patients induce IgG anti-GM1 antibodies in rabbits. J. Neuroimmunol. 104:2000;133-138.
4. Ang C.W., De Klerk M.A., Endtz H.P., Jacobs B.C., Laman J.D., van der Meché F.G., van Doorn P.A. Guillain-Barré syndrome- and Miller Fisher syndrome-associated Campylobacter jejuni lipopolysaccharides induce anti-GM1 and anti-GQ1b antibodies in rabbits. Infect. Immun. 69:2001;2462-2469.
5. Ang C.W., Noordzij P.G., de Klerk M.A., Endtz H.P., van Doorn P.A., Laman J.D. Ganglioside mimicry of Campylobacter jejuni lipopolysaccharides determines antiganglioside specificity in rabbits. Infect. Immun. 70:2002;5081-5085.
6. Arbour N.C., Lorenz E., Schutte B.C., Zabner J., Kline J.N., Jones M., Frees K., Watt J.L., Schwartz D.A. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat. Genet. 25:2000;187-191.
7. Asbury A.K., Cornblath D.R. Assessment of current diagnostic criteria for Guillain-Barré syndrome. [see comments] Ann. Neurol. 27:1990;S21-S24.
8. Baldini M., Lohman I.C., Halonen M., Erickson R.P., Holt P.G., Martinez F.D. A Polymorphism* in the 5′ flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Am. J. Respir. Cell Mol. Biol. 20:1999;976-983.
9. Barton G.M., Medzhitov R. Toll-like receptor signaling pathways. Science. 300:2003;1524-1525.
10. Child N.J., Yang I.A., Pulletz M.C., de Courcy-Golder K., Andrews A.L., Pappachan V.J., Holloway J.W. Polymorphisms in Toll-like receptor 4 and the systemic inflammatory response syndrome. Biochem. Soc. Trans. 31:2003;652-653.
11. Dutch Guillain-Barré Study group Treatment of Guillain- Barré syndrome with high-dose immune globulins combined with methylprednisolone: a pilot study. Ann. Neurol. 35:1994;749-752.
12. Hubacek J.A., Rothe G., Pit'ha J., Skodova Z., Stanek V., Poledne R., Schmitz G. C(-260)→T polymorphism in the promoter of the CD14 monocyte receptor gene as a risk factor for myocardial infarction. Circulation. 99:1999;3218-3220.
13. Hughes R.A., Newsom-Davis J.M., Perkin G.D., Pierce J.M. Controlled trial prednisolone in acute polyneuropathy. Lancet. 2:1978;750-753.
14. Jacobs B.C., van Doorn P.A., Schmitz P.I., Tio-Gillen A.P., Herbrink P., Visser L.H., Hooijkass H., van der Meché F.G. Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome. Ann. Neurol. 40:1996;181-187.
15. Jacobs B.C., Rothbarth P.H., van der Meché F.G., Herbrink P., Schmitz P.I., de Klerk M.A., van Doorn P.A. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology. 51:1998;1110-1115.
16. Kiechl S., Lorenz E., Reindl M., Wiedermann C.J., Oberhollenzer F., Bonora E., Willeit J., Schwartz D.A. Toll-like receptor 4 polymorphisms and atherogenesis. N. Engl. J. Med. 347:2002;185-192.
17. Klein W., Tromm A., Griga T., Fricke H., Folwaczny C., Hocke M., Eitner K., Marx M., Duerig N., Epplen J.T. A polymorphism in the CD14 gene is associated with Crohn disease. Scand. J. Gastroenterol. 37:2002;189-191.
18. Kleyweg R.P., van der Meché F.G., Schmitz P.I. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerve. 14:1991;1103-1109.
19. Kopp E., Medzhitov R. Recognition of microbial infection by Toll-like receptors. Curr. Opin. Immunol. 15:2003;396-401.
20. LeVan T.D., Bloom J.W., Bailey T.J., Karp C.L., Halonen M., Martinez F.D., Vercelli D. A common single nucleotide polymorphism in the CD14 promoter decreases the affinity of Sp protein binding and enhances transcriptional activity. J. Immunol. 167:2001;5838-5844.
21. Lorenz E., Mira J.P., Frees K.L., Schwartz D.A. Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch. Intern. Med. 162:2002;1028-1032.
22. Medzhitov R., Janeway C. Jr. Innate immunity. N. Engl. J. Med. 343:2000;338-344.
23. Myhr K.M., Vagnes K.S., Maroy T.H., Aarseth J.H., Nyland H.I., Vedeler C.A. Interleukin-10 promoter polymorphisms in patients with Guillain- Barré syndrome. J. Neuroimmunol. 139:2003;81-83.
24. Pandey J.P., Vedeler C.A. Immunoglobulin KM genes in Guillain- Barré syndrome. Neurogenetics. 4:2003;147-149.
25. Pasare C., Medzhitov R. Toll-like receptors: balancing host resistance with immune tolerance. Curr. Opin. Immunol. 15:2003;677-682.
26. Picard C., Puel A., Bonnet M., Ku C.L., Bustamante J., Yang K., Soudais C., Dupuis S., Feinberg J., Fieschi C., Elbim C., Hitchcock R., Lammas D., Davies G., Al-Ghonaium A., Al-Rayes H., Al-Jumaah S., Al-Hajjar S., Al-Mohsen I.Z., Frayha H.H., Rucker R., Hawn T.R., Aderem A., Tufenkeji H., Haraguchi S., Day N.K., Good R.A., Gougerot-Pocidalo M.A., Ozinsky A., Casanova J.L. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science. 299:2003;2076-2079.
27. Sheikh K.A., Ho T.W., Nachamkin I., Li C.Y., Cornblath D.R., Asbury A.K., Griffin J.W., McKhann G.M. Molecular mimicry in Guillain-Barré syndrome. Ann. N.Y. Acad. Sci. 845:1998;307-321.
28. Triantafilou M., Triantafilou K. Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster. Trends Immunol. 23:2002;301-304.
29. Triantafilou K., Triantafilou M., Dedrick R.L. A CD14-independent LPS receptor cluster. Nat. Immunol. 2:2001;338-345.
30. van der Meché F.G., Schmitz P.I. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N. Engl. J. Med. 326:1992;1123-1129. (see comments).
31. van der Pol W.L., van den Berg L.H., Scheepers R.H., van der Bom J.G., van Doorn P.A., van Koningsveld R., van den Broek M.C., Wokke J.H., van de Winkel J.G. IgG receptor IIa alleles determine susceptibility and severity of Guillain-Barré syndrome. Neurology. 54:2000;1661-1665.
32. van Koningsveld R., van Doorn P.A., Schmitz P.I., Ang C.W., van der Meché F.G. Mild forms of Guillain-Barré syndrome in an epidemiologic survey in The Netherlands. Neurology. 54:2000;620-625.
33. Van Koningsveld R., Schmitz P.I., Ang C.W., Groen J., Osterhaus A.D., Van der Meché F.G., Van Doorn P.A. Infections and course of disease in mild forms of Guillain-Barré syndrome. Neurology. 58:2002;610-614.
34. Vedeler C.A., Raknes G., Myhr K.M., Nyland H. IgG Fc-receptor polymorphisms in Guillain-Barré syndrome. Neurology. 55:2000;705-707.
35. Visser L.H., Schmitz P.I., Meulstee J., van Doorn P.A., van der Meché F.G. Prognostic factors of Guillain-Barré syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain-Barré Study Group. Neurology. 53:1999;598-604.
36. Wittwer C.T., Ririe K.M., Andrew R.V., David D.A., Gundry R.A., Balis U.J. The LightCycler: a microvolume multisample fluorimeter with rapid temperature control. BioTechniques. 22:1997;176-181.
37. Yuki N., Taki T., Inagaki F., Kasama T., Takahashi M., Saito K., Handa S., Miyatake T. A bacterium lipopolysaccharide that elicits Guillain- Barré syndrome has a GM1 ganglioside-like structure. J. Exp. Med. 178:1993;1771-1775.
38. Ziegler-Heitbrock H.W., Ulevitch R.J. CD14: cell surface receptor and differentiation marker. Immunol. Today. 14:1993;121-125.